2015年至2021年糖尿病性黄斑水肿研究资金支付趋势。
Trends in Research Payments for Diabetic Macular Edema from 2015 to 2021.
作者信息
Lee April M, Xu Timothy T, Starr Matthew R
机构信息
SUNY Downstate College of Medicine, Brooklyn, New York.
Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota.
出版信息
Ophthalmol Sci. 2023 Aug 9;4(2):100379. doi: 10.1016/j.xops.2023.100379. eCollection 2024 Mar-Apr.
PURPOSE
To evaluate characteristics of research payments for diabetic macular edema (DME) studies and correlations to current management trends.
DESIGN
Retrospective cross-sectional study.
SUBJECTS
Research payments for DME.
METHODS
Studies with keywords of "diabetic macular edema" or "DME" in the title were extracted from the Centers of Medicare & Medicaid Services Open Payments database from 2015 to 2021. Recipients, payors, and payment amounts were identified. Industry funding was compared with public research funding by the National Eye Institute (NEI).
MAIN OUTCOME MEASURES
Trends and total value of industry and public fundings for DME from 2015 to 2021.
RESULTS
From 2015 to 2021, 451 beneficiaries received 6062 industry payments for a total of $120 148 997.41 for DME-related research. The total value of industry funding increased from $8 225 859.08 in 2015 to $50 092 778.45 in 2021. Of the 6062 industry payments, 5367 (88.5%) were reported by male recipients compared with 695 (11.5%) female beneficiaries. Payments to female recipients increased from 60 (7.1%) in 2015 to 335 (13.7%) in 2021. In comparison, public funding for DME-related research from the NEI was comprised of $18 863 266.00 to 17 principal investigators from 2015 to 2021. The total value of public funding increased from $973 590.00 in 2015 to $3 354 376.00 in 2021. Of 59 public research payments, 46 (78.0%) were reported by male recipients and 13 (22.0%) by female recipients. Payments to female recipients increased from 1 (25.0%) in 2015 to 3 (30.0%) in 2021. The most highly invested product by industry were anti-VEGF agents, accounting for $89 955 595.20 (74.9%) of total payment value.
CONCLUSIONS
There was an increase in both industry and public-sponsored funding for DME-related research from 2015 to 2021. There seemed to be a possible discrepancy in both industry and public funding based on sex for DME studies during the study period.
FINANCIAL DISCLOSURES
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
目的
评估糖尿病性黄斑水肿（DME）研究的研究经费支付特点及其与当前治疗趋势的相关性。
设计
回顾性横断面研究。
研究对象
DME的研究经费支付情况。
方法
从医疗保险和医疗补助服务中心公开支付数据库中提取2015年至2021年标题中包含“糖尿病性黄斑水肿”或“DME”关键词的研究。确定接受者、支付者和支付金额。将行业资助与美国国立眼科研究所（NEI）的公共研究资助进行比较。
主要观察指标
2015年至2021年DME行业和公共资助的趋势及总价值。
结果
2015年至2021年，451名受益人获得了6062笔行业支付，用于DME相关研究的总金额为120148997.41美元。行业资助的总价值从2015年的8225859.08美元增加到2021年的50092778.45美元。在6062笔行业支付中，男性接受者报告了5367笔（88.5%），女性受益人报告了695笔（11.5%）。支付给女性接受者的金额从2015年的60笔（7.1%）增加到2021年的335笔（13.7%）。相比之下，NEI用于DME相关研究的公共资助包括2015年至2021年向17名主要研究者提供的18863266.00美元。公共资助的总价值从2015年的973590.00美元增加到2021年的3354376.00美元。在59笔公共研究支付中，男性接受者报告了46笔（78.0%），女性接受者报告了13笔（22.0%）。支付给女性接受者的金额从2015年的1笔（25.0%）增加到2021年的3笔（30.0%）。行业投资最多的产品是抗VEGF药物，占支付总价值的89955595.20美元（74.9%）。
结论
2015年至2021年，DME相关研究的行业资助和公共资助均有所增加。在研究期间，DME研究在行业和公共资助方面似乎都存在基于性别的差异。
财务披露
本文末尾的脚注和披露中可能会找到专有或商业披露信息。
Zotero 插件